Krystal Biotech, Inc. Forecast, price target & analysts
Krystal Biotech, Inc. Target price 2026 - Analyst rating & recommendation
Krystal Biotech, Inc. Classifications & Recommendation
Krystal Biotech, Inc. Price Target
| Target Price | $393.72 |
| Price | $336.67 |
| Potential |
16.95%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Krystal Biotech, Inc. 2027 .
The average Krystal Biotech, Inc. target price is $393.72.
This is
16.95%
register free of charge
$497.70
47.83%
register free of charge
$217.15
35.50%
register free of charge
|
|
| A rating was issued by 19 analysts: 17 Analysts recommend Krystal Biotech, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Krystal Biotech, Inc. stock has an average upside potential 2027 of
16.95%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 389.13 | 522.90 |
| 33.94% | 34.38% | |
| EBITDA Margin | 42.92% | 46.20% |
| 14.23% | 7.64% | |
| Net Margin | 52.64% | 44.19% |
| 71.52% | 16.05% |
13 Analysts have issued a sales forecast Krystal Biotech, Inc. 2026 . The average Krystal Biotech, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Krystal Biotech, Inc. EBITDA forecast 2026. The average Krystal Biotech, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 Krystal Biotech, Inc. Analysts have issued a net profit forecast 2026. The average Krystal Biotech, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 6.84 | 7.81 |
| 128.00% | 14.18% | |
| P/E | 43.13 | |
| EV/Sales | 17.44 |
15 Analysts have issued a Krystal Biotech, Inc. forecast for earnings per share. The average Krystal Biotech, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Krystal Biotech, Inc....
Current Krystal Biotech, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Jul 14 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Jun 18 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 16 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 01 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 22 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Jul 14 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Jun 18 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 16 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 01 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 22 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
